{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Daclizumab&page=2",
    "query": {
      "intervention": "Daclizumab",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 76,
    "total_pages": 8,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Daclizumab&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Daclizumab&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T21:46:40.070Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00321555",
      "title": "LMB-2 to Treat Hairy Cell Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hairy Cell Leukemia"
      ],
      "interventions": [
        {
          "name": "Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 15,
      "start_date": "2006-05-02",
      "completion_date": "2022-12-31",
      "has_results": true,
      "last_update_posted_date": "2023-11-14",
      "last_synced_at": "2026-09-30T21:46:40.070Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00321555"
    },
    {
      "nct_id": "NCT00014911",
      "title": "Islet Transplantation for Type 1 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Insulin-Dependent"
      ],
      "interventions": [
        {
          "name": "Islet Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Daclizumab",
          "type": "DRUG"
        },
        {
          "name": "Sulfamethoxazole",
          "type": "DRUG"
        },
        {
          "name": "Ganciclovir",
          "type": "DRUG"
        },
        {
          "name": "Trimethoprim",
          "type": "DRUG"
        },
        {
          "name": "Pentamidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 36,
      "start_date": "2001-04",
      "completion_date": "2010-08",
      "has_results": true,
      "last_update_posted_date": "2017-03-15",
      "last_synced_at": "2026-09-30T21:46:40.070Z",
      "location_count": 5,
      "location_summary": "Miami, Florida • Boston, Massachusetts • Minneapolis, Minnesota + 2 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00014911"
    },
    {
      "nct_id": "NCT00100178",
      "title": "New Onset of Type 1 Diabetes Mycophenolate Mofetil-Daclizumab Clinical Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "Mycophenolate mofeteil (MMF)",
          "type": "DRUG"
        },
        {
          "name": "Daclizumab (DZB)",
          "type": "DRUG"
        },
        {
          "name": "Placebo control for Mycophenolate mofeteil (MMF)",
          "type": "DRUG"
        },
        {
          "name": "Placebo control for Daclizumab (DZB)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "8 Years to 45 Years"
      },
      "enrollment_count": 126,
      "start_date": "2004-05",
      "completion_date": "2008-04",
      "has_results": true,
      "last_update_posted_date": "2020-05-05",
      "last_synced_at": "2026-09-30T21:46:40.070Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • San Francisco, California • Stanford, California + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00100178"
    },
    {
      "nct_id": "NCT00064714",
      "title": "Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "AC2993 (exenatide)",
          "type": "DRUG"
        },
        {
          "name": "daclizumab (immunosuppressive)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 47,
      "start_date": "2003-07",
      "completion_date": "2008-03",
      "has_results": false,
      "last_update_posted_date": "2015-03-11",
      "last_synced_at": "2026-09-30T21:46:40.070Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00064714"
    },
    {
      "nct_id": "NCT00468442",
      "title": "B-Lymphocyte Immunotherapy in Islet Transplantation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Allogeneic Pancreatic Islet Cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Antithymocyte globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Daclizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 2,
      "start_date": "2006-11",
      "completion_date": "2011-09",
      "has_results": false,
      "last_update_posted_date": "2016-03-21",
      "last_synced_at": "2026-09-30T21:46:40.070Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00468442"
    },
    {
      "nct_id": "NCT00048165",
      "title": "A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Heart Transplantation"
      ],
      "interventions": [
        {
          "name": "Daclizumab",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "cyclosporine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 434,
      "start_date": "1999-08",
      "completion_date": "2002-08",
      "has_results": true,
      "last_update_posted_date": "2016-06-13",
      "last_synced_at": "2026-09-30T21:46:40.070Z",
      "location_count": 25,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Tampa, Florida + 19 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00048165"
    },
    {
      "nct_id": "NCT00181142",
      "title": "The Use of Daclizumab and Anti-Thymocyte Globulin in Lung Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Patients Active and Listed for Lung Transplantation"
      ],
      "interventions": [
        {
          "name": "Zenapax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "66 Years",
        "sex": "ALL",
        "summary": "18 Years to 66 Years"
      },
      "enrollment_count": 60,
      "start_date": "1999-10",
      "completion_date": "2004-12",
      "has_results": false,
      "last_update_posted_date": "2017-12-26",
      "last_synced_at": "2026-09-30T21:46:40.070Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00181142"
    },
    {
      "nct_id": "NCT00109161",
      "title": "Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Daclizumab (Anti-CD25 Humanized Monoclonal Antibody)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PDL BioPharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 270,
      "start_date": "2005-04",
      "completion_date": "2006-10",
      "has_results": false,
      "last_update_posted_date": "2008-08-05",
      "last_synced_at": "2026-09-30T21:46:40.070Z",
      "location_count": 30,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Berkeley, California + 26 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Maitland",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00109161"
    },
    {
      "nct_id": "NCT00040248",
      "title": "Daclizumab to Treat Wegener's Granulomatosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Wegener's Granulomatosis"
      ],
      "interventions": [
        {
          "name": "Daclizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 75,
      "start_date": "2002-06",
      "completion_date": "2005-05",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-09-30T21:46:40.070Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00040248"
    },
    {
      "nct_id": "NCT00198146",
      "title": "Prevention of Diabetes Progression Trial (PDPT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Newly Diagnosed With Type 1 Diabetes"
      ],
      "interventions": [
        {
          "name": "Zenapax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "2 Years to 40 Years"
      },
      "enrollment_count": 40,
      "start_date": "2000-07",
      "completion_date": "2007-02-23",
      "has_results": false,
      "last_update_posted_date": "2020-08-11",
      "last_synced_at": "2026-09-30T21:46:40.070Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00198146"
    }
  ]
}